AstraZeneca’s Precision Oncology Approach Applies To Deal, Portfolio Decisions

Key 2026 Data Milestones Include Newer ADCs

 
• By Mandy Jackson
  
AI increasingly informs AstraZeneca's oncology pipeline (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from J.P. Morgan

More from Conferences